9 January 2018 - Erelzi has been added to public drug plan based on specific criteria in Ontario for the treatment of moderate to severe rheumatoid arthritis and for reducing signs and symptoms of active ankylosing spondylitis.

Ontario is the most recent province to have added Erelzi (etanercept) to its public drug plan for the treatment of multiple inflammatory diseases. The provincial listing, effective on 21 December 2017, follows the conclusion of an agreement between the pan-Canadian Pharmaceutical Alliance and Sandoz Canada, allowing member provincial, territorial and federal drug plans to fund this therapy for patients. 

Erelzi was granted Health Canada approval in April 2017 and was launched in Canada in August 2017. Public access to Erelzi is also available in British Columbia and Prince Edward Island.

Read Sandoz press release